

Application No.: 08/487,312

Docket No.: 220002016004

REMARKS

The form of the amendment assumes that the Voluntary Amendment submitted 20 December 2004 has been entered. Support for the optional possibility that the sequence encoding native bovine growth hormone is preceded by a methionine residue at its N-terminus was detailed in that submission. Accordingly, claim 19 has been amended to require that the coding sequence begin at the starting point of the native sequence, but may be preceded by methionine.

In accordance with the request made by the Office, claim 19 has been limited to BGH produced in *E. coli* cells. Therefore, claims 21 and 32-40 have been canceled as redundant. Further, in view of the deletion of "allelic variant" from claim 19, claims 24, 27-28 and 31 have been canceled. Proposed new claims 40 and 42 conform the wording of previously pending claims 25-26 and 29-30 to the modified wording of claim 19. Accordingly, no new matter has been added and entry of the amendment is respectfully requested.

Further, submitted herewith is an Information Disclosure Statement submitting documents not previously submitted in this manner. Also included is a copy of an Information Disclosure Statement submitted in earlier prosecution of this case and acknowledged by the Office. Applicants assume that the documents cited on this latter IDS are of record and available; should this not be the case, applicants will gladly replace them.

Particular attention is called to two documents on the newly submitted IDS – Seavey, B. K., *et al.*, *Biochem/Biophys. Res. Com.* (1971) 43:189-195 which demonstrates that as early as 1971 the presence of two allelic variants of bovine growth hormone was known and Wallis, M., *FEBS Letters* (1973) 35:11-14, which identified the allelic variants as generating BGH with either leucine or valine at position 127.

sd-274373

4

Application No.: 08/487,312

Docket No.: 220002016004

It is believed the amendments to the claims conforms to the requirements of the Office and passage of the proposed claims to issue is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket No. 220002016004.

Respectfully submitted,

Dated: August 9, 2005

By:

Kate H. Murashige
Kate H. Murashige
Registration No. 29,959
MORRISON & FOERSTER LLP
3811 Valley Centre Drive, Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

sd-274373

5